Adamed Pharma expands its production capacity in Pabianice

By expanding the Pabianice plant, Adamed will enhance its production capacity from 2 billion (2020) to 4 billion tablets (2027), and increase the level of automation and robot-aided processes. The General Contractor of the completed first stage of works is ALSTAL Grupa Budowlana.

Innovation and investment are the pillars of Adamed Pharma S.A.’s growth strategy. The company’s R&D activities are aimed at developing modern therapies and laboratory and technological infrastructure as well as upgrading industrial processes. The expansion of the Pabianice plant is one of the key elements of these efforts. The project, which will cost more than PLN 300 million to complete, will bring an increase in the company’s production and warehousing capacities, and support the digitalization of logistics, production and quality processes.

The first stage in the expansion of the Pabianice-based Center included the construction and commissioning of two integrated warehouse facilities for finished products and pharmaceutical materials and a central packaging facility with a total cubic space of 160,000 m3 and a usable area of nearly 19,000 m2, finished in compliance with the pharmaceutical standards.

The commissioning of the new warehouse will triple Adamed’s number of pallet spaces. Prior to the launch of the project, the company had 10,000 storage locations. When the facility is put into service, their number will total 34,000. The reorganization and digitalization of logistics processes will result in a threefold reduction in the time required to receive deliveries of goods and materials, and contribute to improving the quality of logistics services provided to the company’s customers both in Poland and abroad. In addition, the new packaging facility will expand the company’s production capacity and improve the level of standardization and efficiency of packaging medicinal products, including their serialization and aggregation.

The strategic priority of Adamed Pharma S.A.’s activities is securing uninterrupted patient access to medications, and the plan for achieving this goal has been consistently the same, incorporating investments and development. Over the past two decades, Adamed Pharma has allocated over PLN 1.9 billion for investments and R&D projects. The company has plans to spend another billion on investment by 2025. The importance of ensuring that there are no interruptions in the supply chain and the Polish pharmaceutical industry has been made very clear in the context of recent events ranging from the pandemic crisis to the hostilities just across Poland’s eastern border and the associated major geopolitical changes.

As Bartłomiej Rodawski, Chief Operating Officer and Member of the Management Board at Adamed Pharma S.A., notes: The expansion of the Center is well aligned with Adamed’s growth strategy and ideas, including a guarantee of safety as well as responsibility and sustainability. The integrated program for the expansion of the Production and Logistics Center will lead to the doubling of Adamed’s production capacity. As a result, we’ll be able to adapt flexibly and responsibly to the needs of the market, and secure uninterrupted access to modern and effective therapies for Polish patients.

The General Contractor, ALSTAL Grupa Budowlana, has already completed construction works and put in place advanced equipment and technologies required for the commissioning of the site. System testing along with the installation of packaging lines and specialized equipment is still ongoing on the premises of the packaging facility, and expected to be completed in January 2023. A total of 12 packaging lines will be installed when the project is finished.

– The project implemented for Adamed Pharma is extremely important for our company. We’re aware of the function that this purpose-built facility will serve. All the works have been done as per standards and within the agreed timeframes. At present, the investor is fitting the facility with machines and equipment to the highest industry requirements. I’m sure that we’ll soon get together for the opening of the facility. My sincere thanks go to the investor for contributing to our successful collaboration and partnership in project implementation, and to ALSTAL’s employees and associates for their commitment, without which we would not have achieved our goals – says Jarosław Szczupak, President of the Board at ALSTAL Grupa Budowlana.

Photo material: ALSTA Grupa Budowlana Press Office